Understanding Your Risk of Gastroparesis with Ozempic Use

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Evaluation

If you or someone you know has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering whether gastroparesis could be a concern. The established framework of diabetes care has long emphasized glycemic control, but emerging real-world data now prompts a closer look at gastrointestinal side effects in certain patient groups. This page reviews the current understanding of who may be at risk for Ozempic-associated gastroparesis and what the research says about dose and treatment duration.

Ozempic and Gastroparesis: A Clinical Overview

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Its mechanism of action includes slowing gastric emptying, which contributes to its therapeutic effects on glycemic control and satiety. However, this same pharmacodynamic property has been linked to a spectrum of gastrointestinal adverse reactions, including gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation and diagnosis of gastroparesis typically involve a history of persistent upper gastrointestinal symptoms and objective evidence of delayed gastric emptying, often via gastric emptying scintigraphy. The condition can significantly impair quality of life and nutritional status. In the context of Ozempic use, the drug's label reports that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, versus 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not explicitly list gastroparesis as a separate adverse event, the constellation of symptoms—particularly severe nausea, vomiting, and dyspepsia—can be consistent with gastroparesis. Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to functional gastric stasis. In susceptible individuals, this effect may become pathological, resulting in gastroparesis.

Settlement Criteria and Legal Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a central risk consideration. The prescribing information for Ozempic includes a section on hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a distinct adverse reaction. Instead, it groups gastrointestinal symptoms under general adverse reactions, noting that they are more common during dose escalation. This lack of explicit warning may affect settlement-related considerations for affected patients, as it raises questions about whether the manufacturer adequately communicated the risk of severe gastric motility disorders. For patients who develop gastroparesis after Ozempic exposure, settlement criteria typically require evidence of a causal link between the drug and the harm. Key factors include a documented timeline between initiation of Ozempic and onset of gastroparesis symptoms, exclusion of other causes (e.g., diabetes-related autonomic neuropathy, prior gastric surgery, or idiopathic gastroparesis), and medical records confirming the diagnosis. The timeline between exposure and documented harm is critical: symptoms often emerge during dose escalation or after dose increases, as suggested by the higher incidence of gastrointestinal adverse reactions during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who experience persistent symptoms despite dose adjustment or discontinuation may have stronger claims. Settlement-related considerations also involve the severity and duration of harm. Gastroparesis can lead to malnutrition, weight loss, electrolyte imbalances, and hospitalization. The need for ongoing medical management, including dietary modifications, prokinetic agents, or even surgical interventions, may factor into compensation. Additionally, the adequacy of the drug's labeling—specifically, whether the risk of gastroparesis was sufficiently highlighted—could influence liability. The current label does not mention gastroparesis explicitly, which may be argued as a failure to warn. In summary, the evidence from clinical trials indicates that Ozempic is associated with a higher incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, particularly during dose escalation. The mechanistic link through delayed gastric emptying supports a plausible causal pathway. However, the absence of a specific warning for gastroparesis in the prescribing information may be a point of contention in legal claims. Affected patients should document their symptom onset relative to Ozempic use, seek a formal diagnosis, and consult with legal counsel to evaluate their eligibility for settlement based on individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can lead to gastroparesis—a condition of delayed gastric emptying causing nausea, vomiting, and abdominal pain. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically require documented Ozempic use, a confirmed gastroparesis diagnosis, a temporal link between drug initiation and symptom onset, exclusion of other causes, and evidence of harm severity. The lack of explicit gastroparesis warning on the label may strengthen claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.